1. Development of PDX models. PROXC seeks to develop and optimize robust workflows and methodologies for PDX model generation with the goal of assembling a federated collection of PDXs representing the clinical and molecular spectrum of pediatric solid tumors.
2. PDX model sharing. Collaborative research efforts will be empowered by the ability to freely share models and associated clinical and molecular model information across PROXC centers.
3. Standardized preclinical testing approach. Preclinical testing of candidate drugs to support the development of clinical trial concepts and drug prioritization efforts will be conducted across PROXC centers using standardized preclinical testing approaches.
4. Harmonized PDX database. A directory of federated PDX models will be established through an online portal to facilitate the organization of PROXC models and allow investigators to query PROXC model assets based on clinical or molecular characteristics.
5. Resource for the scientific community. PROXC will serve as a resource for external investigators seeking to utilize mouse tumor xenograft models (PDX or CDX – cell line-derived xenograft) for research.
6. PDX biobank. PROXC sites will maintain a bank of viably cryopreserved samples for rederivation of PDX models. Models are stored and maintained at the site from which the model was originally developed. Models can be requested from each site by other PROXC members and can also be readily made available to external investigators.